The U. S. Food and Drug Administration (FDA) on Monday lifted the clinical hold on GH Research Plc's (NASDAQ:GHRS) Investigational New Drug Application (IND) for GH001.

In the trial, people wore the headset once a day for about 20-30 minutes per session In a major shift for how mental health conditions might be treated, the US Food and Drug Administration (FDA) has approved the first at-home brain-stimulation device to treat moderate to severe major depressive disorder (MDD).

Major depressive disorder (MDD) is a widespread and serious mental health condition that affects how people think, feel, and function in daily life.